» Articles » PMID: 20355244

Long-term Efficacy of Perioperative Chemoradiotherapy on Esophageal Squamous Cell Carcinoma

Overview
Specialty Gastroenterology
Date 2010 Apr 1
PMID 20355244
Citations 74
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To investigate the role of perioperative chemoradiotherapy (CRT) in the treatment of locally advanced thoracic esophageal squamous cell carcinoma (ESCC).

Methods: Using preoperative computed tomography (CT)-based staging criteria, 238 patients with ESCC (stage II-III) were enrolled in this prospective study between January 1997 and June 2004. With informed consent, patients were randomized into 3 groups: preoperative CRT (80 cases), postoperative CRT (78 cases) and surgery alone (S) (80 cases). The 1-, 3-, 5- and 10-year survival were followed up. Progression-free survival (PFS) was chosen as the primary endpoint by treatment arm measured from study entry until documented progression of disease or death from any cause. The secondary endpoint was overall survival (OS) determined as the time (in months) between the date of therapy and the date of death. Other objectives were surgical and adjuvant therapy complications.

Results: With median follow-up of 45 mo for all the enrolled patients, significant differences in the 1-, 3-, 5-, 10-year OS (91.3%, 63.5%, 43.5%, 24.5% vs 91%, 62.8%, 42.3%, 24.4% vs 87.5%, 51.3%, 33.8%, 12.5%, P = 0.0176) and PFS (89.3%, 61.3%, 37.5%, 18.1% vs 89.1%, 61.1%, 37.2%, 17.8% vs 84.5%, 49.3%, 25.9%, 6.2%, P = 0.0151) were detected among the 3 arms. There were no significant differences in OS and PFS between the preoperative CRT and postoperative CRT arm (P > 0.05). For the patients who had radical resection, significant differences in median PFS (48 mo vs 61 mo vs 39.5 mo, P = 0.0331) and median OS (56.5 mo vs 72 mo vs 41.5 mo, P = 0.0153) were detected among the 3 arms, but there were no significant differences in OS and PFS between the preoperative CRT and postoperative CRT arm (P > 0.05). The local recurrence rates in the preoperative CRT, postoperative CRT group and S group were 11.3%, 14.1% and 35%, respectively (P < 0.05). No significant differences were detected among the 3 groups when comparing complications but tended to be in favor of the postoperative CRT and S groups (P > 0.05). Toxicities of CRT in the preoperative or postoperative CRT arms were mostly moderate, and could be quickly alleviated by adequate therapy.

Conclusion: Rational application of preoperative or postoperative CRT can provide a benefit in PFS and OS in patients with locally advanced ESCC.

Citing Articles

Comparison of postoperative survival prognosis between early-onset and late-onset esophageal cancer: A Population-based study.

Qin L, Tian J, Zhang Y, Yin Y, Dou Z, Chen J PLoS One. 2024; 19(12):e0315391.

PMID: 39666762 PMC: 11637231. DOI: 10.1371/journal.pone.0315391.


Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.

Porschen R, Fischbach W, Gockel I, Hollerbach S, Holscher A, Jansen P United European Gastroenterol J. 2024; 12(3):399-411.

PMID: 38284661 PMC: 11017771. DOI: 10.1002/ueg2.12523.


Optimal Treatment Strategies for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Real-World Triple Cohort Analysis Using Propensity Score Matching.

Han D, Tian J, Zhao J, Hao S Int J Gen Med. 2023; 16:5467-5479.

PMID: 38021055 PMC: 10676642. DOI: 10.2147/IJGM.S440270.


Clinicopathological characteristics and treatment outcomes of oesophageal cancer patients in Uganda.

Obayo S, Mulumba Y, Thompson C, Gibson M, Cooney M, Orem J Ecancermedicalscience. 2023; 17:1576.

PMID: 37533943 PMC: 10393309. DOI: 10.3332/ecancer.2023.1576.


Current neoadjuvant therapy for operable locally advanced esophageal cancer.

Yang W, Niu Y, Sun Y Med Oncol. 2023; 40(9):252.

PMID: 37498350 DOI: 10.1007/s12032-023-02097-4.


References
1.
Graham A, Shrive F, Ghali W, Manns B, Grondin S, Finley R . Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007; 83(4):1257-64. DOI: 10.1016/j.athoracsur.2006.11.061. View

2.
Triboulet J, Mariette C . [Oesophageal squamous cell carcinoma stade III. State of surgery after radiochemotherapy (RCT)]. Cancer Radiother. 2006; 10(6-7):456-61. DOI: 10.1016/j.canrad.2006.08.002. View

3.
Natsugoe S, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Yokomakura N . Randomized controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006; 19(6):468-72. DOI: 10.1111/j.1442-2050.2006.00615.x. View

4.
Rice T, Adelstein D, Chidel M, Rybicki L, DeCamp M, Murthy S . Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg. 2003; 126(5):1590-6. DOI: 10.1016/s0022-5223(03)01025-0. View

5.
Bonnetain F, Bouche O, Michel P, Mariette C, Conroy T, Pezet D . A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous.... Ann Oncol. 2006; 17(5):827-34. DOI: 10.1093/annonc/mdl033. View